Skip to main content
PMC home page
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2018 Aug 22;9:1900. doi: 10.3389/fmicb.2018.01900

The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health

Marta Olivares 1, Valentina Schüppel 2,3, Ahmed M Hassan 4, Martin Beaumont 1, Audrey M Neyrinck 1, Laure B Bindels 1, Alfonso Benítez-Páez 5, Yolanda Sanz 5, Dirk Haller 2,3, Peter Holzer 4, Nathalie M Delzenne 1,*
PMCID: PMC6113382  PMID: 30186247

Abstract

The Dipeptidyl peptidase-4 (DPP-4) activity influences metabolic, behavioral and intestinal disorders through the cleavage of key hormones and peptides. Some studies describe the existence of human DPP-4 homologs in commensal bacteria, for instance in Prevotella or Lactobacillus. However, the role of the gut microbiota as a source of DPP-4-like activity has never been investigated. Through the comparison of the DPP-4 activity in the cecal content of germ-free mice (GFM) and gnotobiotic mice colonized with the gut microbiota of a healthy subject, we bring the proof of concept that a significant DPP-4-like activity occurs in the microbiota. By analyzing the existing literature, we propose that DPP-4-like activity encoded by the intestinal microbiome could constitute a novel mechanism to modulate protein digestion as well as host metabolism and behavior.

Keywords: DPP-4 activity, PepX activity, gut microbiota, microbiome, metabolism, behavior

DPP-4 activity of human cells

Initially described in the year 1966, the lymphocyte cell surface protein CD26 presents a proteolytic activity that later on was coined as dipeptidyl peptidase-4 (DPP-4; Hopsu-Havu and Glenner, 1966). Besides on lymphocytes, DPP-4 is found on the surface of a variety of cells, primarily endothelial and epithelial cells, and in the blood in a soluble form (Zhong et al., 2015; Klemann et al., 2016). The proteolytic activity of DPP-4 consists in the cleavage of peptides when proline or alanine is present at the penultimate position of the peptide's N-terminus. The DPP-4 activity takes part in the digestion of dietary proteins (Do et al., 2014) and introduces modifications in bioactive peptides modulating their activity and function (Rosmaninho-Salgado et al., 2012; Cuenco et al., 2017). The listing of potential substrates of DPP-4 activity is broad, ranging from dietary proteins to gut hormones, neuropeptides, and chemokine's (Table 1). Alterations in DPP-4 activity or expression are found in metabolic, intestinal and behavior-related processes, and have led to propose the DPP-4 activity as an essential regulator of different physiological (dys)functions (Elgun et al., 1999; El Yacoubi et al., 2006; Detel et al., 2007; Stengel et al., 2014). Besides, several subsets of immune cells also express on the surface DPP-4, where it plays a signaling role independent on any proteolytic activity (Klemann et al., 2016).

Table 1.

Selection of some of the substrates of dipeptidyl peptidase-4 (DPP-4) activity [adapted from (Klemann et al., 2016)].

Peptide N-terminus Biological effect
Glucagon family GLP-1 HA↓EG↓TF… Inactivation
GIP YA↓EGTF… Inactivation
GLP-2 HA↓DG↓SF… Inactivation
GHRH YA↓DAIF Inactivation
Neuropeptides Enterostatin VP↓DP↓R Inactivation
Substance P RP↓KP↓Q… Inactivation
GRP VP↓LP↓AG… Inactivation
β-casomorphin YP↓FVEPI Inactivation
Endomorphin-1 YP↓FF-NH2 Inactivation
Endomorphin-2 YP↓WF-NH2 Change in receptor preference
Morphiceptin YP↓FP-NH2 Inactivation
Pancreatic polypeptides PYY YP↓IKPE… Change in receptor preference
NPY YP↓SKPD… Change in receptor preference
Chemokines RANTES (CCL5) SP↓YSSD… Change in receptor preference
Eotaxin (CCL11) GP↓ASVP… Inactivation
MDC (CCL22) GP↓YG↓AN Change in receptor preference
MIG (CXCL9) TP↓VVRK Inactivation
IP-10 (CXCL10) VP↓LSRT Inactivation
I-TAC (CXCL11) FP↓MFKR Inactivation
SDF-1α KP↓VSLS… Inactivation
Open in a new tab

GHRH, growth hormone releasing hormone; GIP, gastric inhibitory polypeptide; GLP, glucagon-like peptide; GRP, gastrin-releasing peptide; IP-10, interferon gamma-induced protein 10; I-TAC, interferon-inducible T-cell α chemoattractant; MDC, macrophage-derived chemokine; MIG, monokine induced by gamma interferon; NPY, neuropeptide Y; PYY, peptide YY; RANTES, regulated upon activation, normal T-cell expressed and secreted; SDF-1, stromal cell-derived factor 1.

The gut microbiota exhibits DPP-4-like activity that could be implicated in human health

Intense research has improved our understanding of the roles of DPP-4 activity. However, the studies performed so far have only considered the DPP-4 activity of human cells without taking into account that certain fungi and bacteria, part of the human-associated microbial communities, can also exhibit this enzymatic activity (Wallace et al., 1997; Matos et al., 1998; Varmanen et al., 2000; Goldstein et al., 2001; Sanz and Toldra, 2001; Anastasiou et al., 2002; Glaser et al., 2002; Shibata et al., 2003; Walker et al., 2003; Cooper and Woods, 2009; Stressler et al., 2013; Fteita et al., 2015, 2017; Üstün-Aytekin et al., 2016). Only one study has tackled this issue when describing that the DPP-4 activity of the fungus Blastomyces dermatitidis, an opportunistic pathogen that can colonize the lungs, cleaves chemokines with deleterious consequences for local infection (Sterkel et al., 2016). The gut microbiota that permanently colonizes the gastrointestinal tract influences the host metabolism and immune function (Sommer and Bäckhed, 2013; Cani, 2017). The possible roles of DPP-4-like activity exhibited by the gut microbiota itself have never been investigated even if several references describe the existence of DPP-4 activity in Prevotella (Wallace et al., 1997; Shibata et al., 2003; Walker et al., 2003; Fteita et al., 2015, 2017), and a counterpart activity to the DPP-4 (called Xaa-Pro dipeptidyl-peptidase or PepX activity) is found in Lactobacillus, Lactococcus, and Streptococcus. (Matos et al., 1998; Varmanen et al., 2000; Goldstein et al., 2001; Sanz and Toldra, 2001; Anastasiou et al., 2002; Glaser et al., 2002; Stressler et al., 2013; Üstün-Aytekin et al., 2016). Besides, the gut microbiota interacts with nutrients and drugs modulating nutritional or pharmacological therapeutic approaches (Delzenne and Bindels, 2018). As one of the strategies in the management of diabetes consists of the inhibition of the DPP-4 activity, it is particularly interesting to investigate the relevance of the DPP-4 activities produced by the gut microbes. A very recent study conducted in our laboratory has, indeed, shown that the administration of the DPP-4 inhibitor vildagliptin can also inhibit the DPP-4 activity in microbial habitats like the cecal content and feces of mice (Olivares et al., 2018). Here, we hypothesize that DPP-4-like activity produced by the gut microbiota (sum of bacterial DPP-4 plus PepX activities) could be a new mechanism through which the microbes influence physiological or pathological processes in humans. Our hypothesis is based on the key role attributed to DPP-4 in mammals, which could be partly accomplished by the DPP-4-like activity of microbial origin. In the first part of this article, we introduce the features of DPP-4-like activity of microbial origin. Next, we provide the first evidence for DPP-4-like activity produced by the gut microbiota in vivo. Finally, we describe how, theoretically, the gut microbial DPP-4-like activity could influence host digestion, metabolism, and behavior.

Characteristics of DPP-4-like activity in microbes and eukaryotic cells

Broadly, all peptidases catalyze the same reaction, the hydrolysis of a peptide bond. However, peptidases do so with a high selectivity. When an enzyme hydrolyzes the N-terminal dipeptide with proline or alanine at the penultimate place, the activity is named X-prolyl dipeptidyl aminopeptidase (Rawlings et al., 2016). There are two families of enzymes that catalyze this reaction: the S9B and S15 peptidase families (Figure 1). Both share the motif GXSYXG as a consensus for the X-prolyl dipeptidyl aminopeptidase activity (Rawlings et al., 2016).

Figure 1.

Figure 1

Open in a new tab

Families with X-prolyl dipeptidyl aminopeptidase activities. The S9B family includes the Dipeptidyl peptidase-4 activity form mammalian cells and Gram-negative bacteria (Prevotella). The counterpart activity, so-called Xaa-Pro dipeptidyl peptidase or PepX activity is present in Gram-positive bacteria (Lactobacillus, Lactococcus, Streptococcus).

Family S9B: DPP-4

The typical example of the peptidase family S9B is the DPP-4 from mammalian cells (Rawlings et al., 2016). DPP-4 exists in two isoforms: as a homodimer anchored to the membrane of different cell types (i.e., enterocytes, endothelial or immune cells), and as a soluble circulating form (Zhong et al., 2015; Klemann et al., 2016). When expressed on the surface of mammalian cells, the structure consists of a cytoplasmic region, a transmembrane portion, and an extracellular tail with the catalytic triad (Klemann et al., 2016). The soluble form is thought to be released from the membrane of immune cells to the blood (Gorrell et al., 2001; Cordero et al., 2009). The DPP-4 activity is highly conserved and can also be found in fungi and certain Gram-negative bacteria, like in certain species of the genus Prevotella (Wallace et al., 1997; Shibata et al., 2003; Walker et al., 2003; Fteita et al., 2015, 2017). The DPP-4 from eukaryotic and prokaryotic organisms present a very similar amino acid sequences and in both cases, it corresponds to the number 3.4.14.5 according to the Enzyme Commission (Shibata et al., 2003; Walker et al., 2003).

Family S15: xaa-pro dipeptidyl peptidase or PepX activity

The typical example of the peptidase family S15 is the Xaa-Pro dipeptidyl peptidase from Lactococcus lactis coded by the pepX gene, and consequently named PepX activity (Rawlings et al., 2016). This can be found in lactic acid bacteria, such as Lactobacillus, Lactococcus, and Streptococcus (Matos et al., 1998; Varmanen et al., 2000; Goldstein et al., 2001; Sanz and Toldra, 2001; Anastasiou et al., 2002; Glaser et al., 2002; Stressler et al., 2013; Üstün-Aytekin et al., 2016). PepX is a cytosolic enzyme associated with the oligopeptide transporter oppA. OppA introduces oligopeptides into the bacterium that afterwards, are cleaved by the PepX activity (Wang et al., 2012). The PepX and DPP-4 activities are described as counterparts, meaning that both cleave the same peptide bond. However, despite sharing the same selectivity toward the peptide bond, there is no similarity in their amino acid sequence beyond the residues implicated in the enzymatic activity (Walker et al., 2003; Rigolet et al., 2005). According to the Enzyme Commission, the PepX activity corresponds to the entry 3.4.14.11.

DPP-4 and PepX activities described in bacteria of the gut microbiota

The Table 2 summarizes the bacterial members of the intestinal microbiota with reported DPP-4 or PepX activities. In ruminants, the DPP-4 activity of Prevotella is described as one of the enzymes that break down peptides in the rumen (Walker et al., 2003). In the human oral microbiome, the DPP-4 activity of Prevotella has been considered as a virulence factor involved in the biofilm formation and the onset of periodontal disease (Fteita et al., 2017). In Lactobacillus and Lactococcus, the PepX activity has been studied in the field of food technology as it contributes to the hydrolysis of bitter proline-containing peptides influencing texture and flavor of dairy and fermented meat products (Sanz and Toldra, 2001; Gatti et al., 2008). Also, the PepX activity is involved in the generation of bioactive peptides from casein (Stressler et al., 2013). In the genus Streptococcus, the pepX gene is described as one of the genes required for the infection processes of Streptococcus gordonii-responsible for bacterial endocarditis- and Streptococcus agalactiae-causative of neonatal sepsis- (Goldstein et al., 2001; Glaser et al., 2002).

Table 2.

Commensal bacteria of the gut microbiota with reported DPP-4 activity.

Family Gen Protein ID Bacterial specie References
S9B dpp4 Dipeptidyl peptidase-4 3.4.14.5 Prevotella aurantiaca Fteita et al., 2015, 2017
Prevotella intermedia Shibata et al., 2003; Fteita et al., 2015
Prevotella nigrescens Fteita et al., 2015
Prevotella pallens Fteita et al., 2015
Prevotella albensis Walker et al., 2003
Prevotella ruminicola Wallace et al., 1997
S15 pepX X-prolyl dipeptidyl peptidase or PepX activity 3.4.14.11 Lactobacillus helveticus Stressler et al., 2013
Lactobacillus sakei Sanz and Toldra, 2001
Lactobacillus rhamnosus Varmanen et al., 2000
Lactococcus lactis Matos et al., 1998; Üstün-Aytekin et al., 2016
Streptococcus thermophilus Anastasiou et al., 2002
Streptococcus gordonii Goldstein et al., 2001
Streptococcus agalactiae Glaser et al., 2002
Open in a new tab

The intestinal microbiota presents DPP-4-like activity: proof of concept

The consideration of the intestinal microbiota as a source of DPP-4-like activity is an entirely new concept. In order to prove this hypothesis, we have analyzed the activity and expression of DPP-4 in samples of germ-free mice (GFM) and gnotobiotic mice colonized with feces of a lean subject (see Supplemental Material and Methods).

In GFM, the DPP-4 activity in the cecal content represents the activity that is released from eukaryotic cells. The renewal of enterocytes drives the shedding of intestinal tissue constituents into the lumen (including DPP-4) (Rawlings et al., 2016). In colonized mice, the DPP-4 activity was significantly higher compared to GFM (p < 0.001) (Figure 2A). This increase is attributed to the DPP-4-like activity produced by the intestinal microbiota. Our conclusion is reinforced by the absence of differences in the DPP-4 activity and Dpp-4 expression in the cecal tissue between the GFM and the colonized mice (Figures 2B,C). The slight but not significant reduction of the DPP-4 activity in the cecal tissue of the colonized mice (p = 0.087) is in agreement with two previous studies reporting a decrease of the activity in the brush-border of germ-free piglets and rats compared to the colonized equivalents (Kozáková et al., 1998; Kozakova et al., 2006). Conversely in B10.BR/SnPh mice, it has been reported an absence of differences in the DPP-4 activity in the brush-border between GFM, gnotobiotic and conventional mice at 3 weeks-old (Kozáková et al., 2001). However, when the mice were older (8 weeks-old), GFM presented lower DPP-4 activity (Kozáková et al., 2001). A higher cell renewal due to stimulation by the gut microbiota could have increased the DPP-4 activity of colonized mice; however, this hypothesis is not confirmed across studies, and besides it depends on the age of the mice. In the present study, we did not find differences in the DPP-4 activity or expression in the intestinal tissue between GFM and colonized C57Bl6/N mice (16 weeks-old). Thus, we can state that the increase in the DPP-4 activity in the cecal content of colonized mice is produced by the intestinal bacteria.

Figure 2.

Figure 2

Open in a new tab

Dipeptidyl peptidase-4 in the (A) cecal content and (B) cecal tissue, and (C) Dpp4 expression in the cecal tissue of germ-free mice (GFM) and mice colonized with healthy gut microbiota. Data were analyzed with the t-test for unpaired samples. Significant differences are represented by the symbol ***(p < 0.001).

DPP-4-like activity of the gut microbiota: potential impact on host physiology and health?

The DPP-4 and PepX activities produced by the gut microbiota might influence host physiological functions if they can cleave substrates with a biological activity, like dietary peptides, gut hormones or neuropeptides. We elaborated different scenarios in which the DPP-4 and PepX activities of the gut microbiota might impact nutrient digestion and host metabolism and behavior, in view of the existing literature (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Theoretical scenarios in which the Dipeptidyl peptidase-4 and PepX activities produced by the gut microbiota might impact host's health through the proteolysis of different substrates with a biological activity. Glucagon-like peptide-1 (GLP)-1, gastric inhibitory polypeptide (GIP), and peptide YY (PYY) are represented in color (purple, green and blue, respectively) when not cleaved by DPP-4 and PepX activities. The corresponding symbols are represented in black after the cleavage by DPP-4 and PepX activities.

Digestion of proteins

During the digestion, protein and oligopeptides are hydrolyzed by pancreatic proteases. Smaller peptides are, then, cleaved by brush-border peptidases to produce free amino acids and di- and tripeptides. The DPP-4 activity at the surface of enterocytes is one of the peptidases involved in the last step of protein digestion (Do et al., 2014). The DPP-4 activity is produced all along the intestinal tract, but the activity is higher in the ileum than in the caecum or colon (Olivares et al., 2018). As mentioned above, the DPP-4 activity results in the release of a dipeptide if proline or alanine is present at the penultimate position. Interestingly, human gastrointestinal proteases are unable to degrade dietary proteins with high proline content, and then, we hypothesize that enzymatic activities of the intestinal bacteria, including the DPP-4 or PepX activities, can contribute to their digestion (Shan et al., 2005). The interest of the proteolytic activity of the gut microbiota has been demonstrated in food intolerances triggered by gluten, a group of proteins characterized by a high proline content, but these studies were not particularly focused on the DPP-4 or PepX activities (Laparra and Sanz, 2010; Caminero et al., 2016). The role of the PepX activity in the breakdown of gluten has been studied, for instance, to obtain sourdough free of gluten (De Angelis et al., 2010). More specifically, fungal proteases from Aspergillus oryzae and Aspergillus niger can release polypeptides from gluten, which are subsequently transported inside lactic acid bacteria and hydrolyzed (De Angelis et al., 2010). In this process at least three peptidases, the PepX activity, the aminopeptidase type N (PepN), and endopeptidase O (PepO), are necessary to detoxify the immunogenic epitopes of gluten in the sourdough (De Angelis et al., 2010).

On the other hand, a high proteolytic activity of the intestinal microbiota has long been regarded as detrimental since some bacterial metabolites produced from amino acid degradation (i.e., H2S, ammonia, and phenol) are toxic for the epithelium (Blachier et al., 2007). However, more recent data have shown that other compounds produced by intestinal bacteria from amino acids, such as indole, are protective for the mucosa (Bansal et al., 2010). The consequences of an increase in bacterial proteolytic activity for the host are difficult to predict and, thus, the exact significance of the DPP-4-like activity of the microbiota as a player in the cleavage of dietary proteins warrants to be investigated.

Host metabolism

The role of DPP-4 activity in the control of glucose metabolism is the one most extensively studied (Zhong et al., 2015). After nutrient ingestion, enteroendocrine cells (L and K cells) release gut hormones, like incretins, into the bloodstream. The two main incretins, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are among the list of substrates of the DPP-4 activity (Seino et al., 2010) (Table 1). As a result, GLP-1 and GIP present a short half-life because the DPP-4 activity of hematopoietic and endothelial cells rapidly inactivates them (Mulvihill et al., 2017). Consequently, Dpp-4 knockout (KO) mice showed an improved glucose tolerance associated with increases in the GLP-1 levels (Marguet et al., 2000). In humans, this effect is achieved by the administration of DPP-4 inhibitors, a type of antidiabetic agents that preserve the active form of incretins (Zhong et al., 2015).

Strong evidence corroborates a link between the gut microbiota and glucose homeostasis (Delzenne et al., 2015). In that sense, several approaches have aimed to handle the gut microbiota to promote the release and activity of intestinal hormones. For instance, the stimulation of the production of GLP-1 through the administration of prebiotic nutrients (that change the commensal gut microbiota composition and activity), has proven efficacy for improving glucose metabolism and satiety in humans and animal models (Delzenne et al., 2011; Everard and Cani, 2014). Also, the use of commensal bacteria, as Lactobacillus, able to release GLP-1 analogs has been proposed as an innovative way to improve host functions related to energy and glucose metabolism (Lin et al., 2016). As a fresh perspective, could the DPP-4 and PepX activities produced by the gut microbiota inactivate GLP-1 and GIP, thereby impairing glucose homeostasis as a consequence? For this purpose, DPP-4 and PepX activities would need to be released and cross the gut barrier to interact with the gut hormones. Mice KO for Dpp-4 gene and fed with a control diet exhibit in the plasma a residual DPP-4 enzymatic activity (~10% compared to the wild-type mice) whose origin is unknown (Marguet et al., 2000). This activity could, at least in part, come from the translocation of DPP-4 activity from the microbiota and that even if the amount of enzyme were small, it may have an effect on the host's metabolism. Accordingly, for instance, previous human studies have reported that overweight and obese subjects in comparison to normal-weight subjects present an increase in the DPP-4 activity of 2.7 and 13.5%, that is associated with decreases in active GLP-1 of 22.5 and 27.7%, respectively (Ahmed et al., 2017). Also, animal studies performed in our group have shown that the administration of prebiotics causes a drop of the DPP-4 activity of the 23.1% that is associated with a double concentration in the active form of GLP-1 (Cani et al., 2005). So, previous data seems to point out that small changes in the DPP-4 activity can be associated large changes in the active form of GLP-1. However, the translocation of active enzymes from the gut microbiota to host organs or tissues, or the inactivation of GLP-1 and GIP by activities different from host enzymes has never been demonstrated and remains hypothetical, as well as the connection between the increases in Prevotella in metabolic disorders and the DPP-4 activity of a bacterial origin (Pedersen et al., 2016). Some recent evidence shows the translocation of a bacterial protein (i.e., caseinolytic protease Clp B produced by E. coli) in the intestine that mimics the action of α-melanocyte-stimulating hormone and controls pathways of host satiety (Breton et al., 2016). In the case of the DPP-4, much remains to be investigated to unravel if the DPP-4 activity produced by the gut microbiota could play any role in the host metabolism.

Satiety and emotional-affective behavior

The communication that is established between the gut and the brain is known as the gut-brain axis. Among the molecules involved in this dynamic exchange of information are some gut hormones, like the neuropeptide Y (NPY) and peptide YY (PYY) (Holzer et al., 2012). PYY is exclusively expressed by endocrine cells of the digestive system, whereas NPY is found in several cell systems at distinct levels of the gut-brain axis (for instance, enteric and sympathetic neurons; Holzer et al., 2012). DPP-4 also modulates the functionality of NPY and PYY (Table 1). DPP-4 can cleave off the N-terminal dipeptide enhancing the agonistic activity of the shortened PYY (PYY3−36) at Y2 receptors. In this way, the effect of PYY in the ileal and colonic brake of digestion and in the induction of satiety via activation of hypothalamic Y2 receptors can be enhanced (Cox, 2007; Holzer et al., 2012). However, the role of DPP-4 in the regulation of satiety has not yet been fully sorted out. Thus, DPP-4 deactivates GLP-1 but enhances the activity of NPY, and PYY at Y2 receptors. While Dpp-4 KO mice are protected against obesity (Conarello et al., 2003), DPP-4 inhibitors lack an effect on body weight in humans (Karagiannis et al., 2012).

There is some evidence indicating that DPP-4 is also involved in the regulation of emotional-affective behavior. Dpp-4 KO mice exhibit an anti-depressive and hyperactive phenotype (El Yacoubi et al., 2006). Likewise, DPP-4-deficient congenic rats showed enhanced stress resilience (Canneva et al., 2015). The DPP-4 inhibitor sitagliptin has an antidepressant effect as it reduces the immobility time in the forced swim test and tail suspension test in mice, and prevents the high fat diet-induced prolongation of immobility time in the forced swim test in rats (Kamble et al., 2016; Magdy et al., 2017). In humans, incretin-based therapies, which include DPP-4 inhibitors and GLP-1 analogs, reduce depression symptoms in patients who have type 2 diabetes. This antidepressant effect of incretins was independent of their effect on hemoglobin A1C (Moulton et al., 2016). The mechanism of the antidepressant effect of DPP-4 inhibition remains unclear but could be related to changes in the functionality of GLP-1, NPY, and PYY, given that enhancement of GLP-1 and Y1 receptor signaling has an antidepressant action (Redrobe et al., 2002; Isacson et al., 2011; Anderberg et al., 2016). In rodents, DPP-4 inhibitors reduce neuronal loss and cognitive impairment in ischemic stroke, an effect which is independent of the hypoglycemic action of DPP-4 (Shannon, 2013; Ma et al., 2015). It is worth noting that DPP-4 inhibitors do not cross the blood-brain barrier, which implies that the neuroprotective effect of DPP-4 inhibitors is mediated by a peripheral route rather than by central inhibition of DPP-4 (Shannon, 2013). DPP-4-like of bacterial origin has never been assessed as a potential modulator of food related-behavior, mood or depression. Once again, this must be evaluated taking into account the complexity of the processes linking the gut to the brain functions.

DPP-4 in gut inflammation and visceral pain

As DPP-4 plays a substantial role in the immune system, particularly in T cell function, DPP-4 has been investigated as a possible target for treating autoimmune diseases including inflammatory bowel disease (Klemann et al., 2016). While circulating DPP-4 activity and the amount of the enzyme in plasma and colon is reduced in patients with active Crohn's disease, DPP-4 positive lymphocytes are higher in patients compared to healthy controls (Hildebrandt et al., 2001; Moran et al., 2012). Importantly, the effects of pharmacological DPP-4 inhibition and Dpp4 KO on intestinal inflammation are not consistent with each other. While systemic and topical DPP-4 inhibitors reduce colitis severity and promote healing of colitis (Mimura et al., 2013; Salaga et al., 2017), Dpp4 KO does not protect from colitis (Geier et al., 2005) but increases colonic myeloperoxidase activity and nuclear factor κbp65 subunit and modifies leucocyte trafficking (Detel et al., 2012). The substrates of DPP-4 include several pain-modifying mediators as endomorphin-2 and substance P (Table 1). Accordingly, Dpp4 KO in mice promoted increases of the substance P concentrations in the plasma but not in the brain (Guieu et al., 2006). This effect is associated with reduced latency in the hot plate and tail pinch tests, a change that reflects mechanical and thermal hyperalgesia (Guieu et al., 2006). In clinical practice, DPP-4 inhibitors occasionally lead to arthritis and arthralgia (Mascolo et al., 2016). As regards visceral pain, several DPP-4 substrates are involved in the regulation of visceral nociception. For example, the GLP-1 analog liraglutide reduces visceral hypersensitivity induced by lipopolysaccharide injection and water avoidance stress in rats (Nozu et al., 2018). ROSE-010, another GLP-1 analog, reduces visceral pain in patients suffering from irritable bowel syndrome (Hellström et al., 2009). The KO of Pyy or Y1 receptors in mice and the pharmacological blockade of peripheral Y2 receptors, increase sensitivity to visceral pain which suggests an involvement of PYY and other Y1 and Y2 receptor ligands in the regulation of visceral pain sensitivity (Naveilhan et al., 2001; Hassan et al., 2017). Any involvement of microbial DPP-4-like in the bioavailability of gut hormones regulating visceral pain sensitivity and colitis remains to be explored.

Conclusion

The host-microbiota cross-talk involves interactions with dietary factors and mediators of the neuroendocrine and immune systems. Here we provide new evidence of the ability of gut microbiota to produce DPP-4-like activity by comparing GFM and colonized mice. We describe the different contexts in which microbial DPP-4 activity could be interesting to evaluate. The functions of the DPP-4-like homolog expressed in the gut microbiota could influence dietary protein digestion and thereby contribute to the change in the host response toward these peptides. The influence on the modulation of host endocrine peptides, which play crucial roles in the metabolism and behavior, are more hypothetical given the lack of data reporting the potential translocation of DPP-4-like from the gut lumen to host tissues. Future experiments are needed to investigate this hypothetical mechanism and potential quantitative contribution of these bacterial activities. This hypothesis paper suggests another way by which the gut microbiota may contribute to nutrients metabolism, and thereby affect host physiology. If confirmed in humans, it will significantly contribute to the progress in our understanding of the links between the human microbiome and human diseases.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon justified request.

Ethics statement

Mouse experiments were performed with permission of the German animal welfare authorities at the district government (Regierung von Oberbayern, reference number 55.2-1-54-2532-27-14).

Author contributions

MO, AH, MB, PH, and ND drafted the original manuscript. MO prepared the figures. VS and DH performed the animal experiment. MO acquired the data and analyzed the data. All authors (MO, VS, AH, MB, AN, LB, AB-P, YS, DH, PH, and ND) provided intellectual input, contributed to discussion and approval of the final manuscript. ND supervised the manuscript preparation and is the guarantor of this work.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Glossary

Abbreviations

DPP-4

Dipeptidyl peptidase-4

GFM

germ-free mice

GLP

Glucagon-like peptide

GIP

Gastric inhibitory polypeptide

KO

Knockout

PYY

Peptide YY

NPY

Neuropeptide Y.

Footnotes

Funding. This work was supported by EU grant 613979 (MyNewGut). MO is a beneficiary of a “MOVE-IN Louvain” Incoming Post-doctoral Fellowship co-funded by UCLouvain and the Marie Curie Actions of the European Commission.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.01900/full#supplementary-material

Click here for additional data file. (19KB, docx)

References

  1. Ahmed R. H., Huri H. Z., Muniandy S., Al-Hamodi Z., Al-Absi B., Alsalahi A., et al. (2017). Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clin. Biochem. 50, 746–749. 10.1016/j.clinbiochem.2017.03.008 [DOI] [PubMed] [Google Scholar]
  2. Anastasiou R., Papadelli M., Georgalaki M. D., Kalantzopoulos G., Tsakalidou E. (2002). Cloning and sequencing of the gene encoding X-prolyl-dipeptidyl aminopeptidase (PepX) from Streptococcus thermophilus strain ACA-DC 4. J. Appl. Microbiol. 93, 52–59. 10.1046/j.1365-2672.2002.01659.x [DOI] [PubMed] [Google Scholar]
  3. Anderberg R. H., Richard J. E., Hansson C., Nissbrandt H., Bergquist F., Skibicka K. P. (2016). GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65, 54–66. 10.1016/j.psyneuen.2015.11.021 [DOI] [PubMed] [Google Scholar]
  4. Bansal T., Alaniz R. C., Wood T. K., Jayaraman A. (2010). The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc. Natl. Acad. Sci. U.S.A. 107, 228–233. 10.1073/pnas.0906112107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blachier F., Mariotti F., Huneau J. F., Tomé D. (2007). Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences. Amino Acids 33, 547–562. 10.1007/s00726-006-0477-9 [DOI] [PubMed] [Google Scholar]
  6. Breton J., Tennoune N., Lucas N., Francois M., Legrand R., Jacquemot J., et al. (2016). Gut commensal, E. coli proteins activate host satiety pathways following nutrient-induced bacterial growth. Cell Metab. 23, 324–34. 10.1016/j.cmet.2015.10.017 [DOI] [PubMed] [Google Scholar]
  7. Caminero A., Galipeau H. J., McCarville J. L., Johnston C. W., Bernier S. P., Russell A. K., et al. (2016). Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology 151, 670–683. 10.1053/j.gastro.2016.06.041 [DOI] [PubMed] [Google Scholar]
  8. Cani P. D. (2017). Gut microbiota-at the intersection of everything? Nat. Rev. Gastroenterol. Hepatol. 14, 321–322. 10.1038/nrgastro.2017.54 [DOI] [PubMed] [Google Scholar]
  9. Cani P. D., Neyrinck A. M., Maton N., Delzenne N. M. (2005). Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. Obes. Res. 13, 1000–1007. 10.1038/oby.2005.117 [DOI] [PubMed] [Google Scholar]
  10. Canneva F., Golub Y., Distler J., Dobner J., Meyer S., von Hörsten S. (2015). DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. Psychoneuroendocrinology 53, 195–206. 10.1016/j.psyneuen.2015.01.007 [DOI] [PubMed] [Google Scholar]
  11. Conarello S. L., Li Z., Ronan J., Roy R. S., Zhu L., Jiang G., et al. (2003). Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 100, 6825–6830. 10.1073/pnas.0631828100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cooper K. G., Woods J. P. (2009). Secreted dipeptidyl peptidase IV activity in the dimorphic fungal pathogen Histoplasma capsulatum. Infect. Immun. 77, 2447–2454. 10.1128/IAI.01345-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cordero O. J., Salgado F. J., Nogueira M. (2009). On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 58, 1723–1747. 10.1007/s00262-009-0728-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cox H. M. (2007). Peptide YY: a neuroendocrine neighbor of note. Peptides 28, 345–351. 10.1016/j.peptides.2006.07.023 [DOI] [PubMed] [Google Scholar]
  15. Cuenco J., Minnion J., Tan T., Scott R., Germain N., Ling Y., et al. (2017). Degradation paradigm of the gut hormone, pancreatic polypeptide, by hepatic and renal peptidases. Endocrinology 158, 1755–1765. 10.1210/en.2016-1827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. De Angelis M., Cassone A., Rizzello C. G., Gagliardi F., Minervini F., Calasso M., et al. (2010). Mechanism of degradation of immunogenic gluten epitopes from Triticum turgidum L. var. durum by sourdough lactobacilli and fungal proteases. Appl. Environ. Microbiol. 76, 508–18. 10.1128/AEM.01630-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Delzenne N. M., Bindels L. B. (2018). Gut microbiota in 2017: Contribution of gut microbiota-host cooperation to drug efficacy. Nat. Rev. Gastroenterol. Hepatol. 15, 69–70. 10.1038/nrgastro.2017.170 [DOI] [PubMed] [Google Scholar]
  18. Delzenne N. M., Cani P. D., Everard A., Neyrinck A. M., Bindels L. B. (2015). Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 58, 2206–2217. 10.1007/s00125-015-3712-7 [DOI] [PubMed] [Google Scholar]
  19. Delzenne N. M., Neyrinck A. M., Bäckhed F., Cani P. D. (2011). Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat. Rev. Endocrinol. 7, 639–646. 10.1038/nrendo.2011.126 [DOI] [PubMed] [Google Scholar]
  20. Detel D., Persic M., Varljen J. (2007). Serum and intestinal dipeptidyl peptidase IV (DPP IV/CD26) activity in children with celiac disease. J. Pediatr. Gastroenterol. Nutr. 45, 65–70. 10.1097/MPG.0b013e318054b085 [DOI] [PubMed] [Google Scholar]
  21. Detel D., Pugel E. P., Pucar L. B., Buljevic S., Varljen J. (2012). Development and resolution of colitis in mice with target deletion of dipeptidyl peptidase IV. Exp. Physiol. 97, 486–496. 10.1113/expphysiol.2011.061143 [DOI] [PubMed] [Google Scholar]
  22. Do T. T., Hindlet P., Waligora-Dupriet A. J., Kapel N., Neveux N., Mignon V., et al. (2014). Disturbed intestinal nitrogen homeostasis in a mouse model of high-fat diet-induced obesity and glucose intolerance. Am. J. Physiol. Endocrinol. Metab. 306, E668–E680. 10.1152/ajpendo.00437.2013 [DOI] [PubMed] [Google Scholar]
  23. El Yacoubi M., Vaugeois J. M., Marguet D., Sauze N., Guieu R., Costentin J., et al. (2006). Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity. Behav. Brain Res. 171, 279–285. 10.1016/j.bbr.2006.04.003 [DOI] [PubMed] [Google Scholar]
  24. Elgun S., Keskinege A., Kumbasar H. (1999). Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression. Psychoneuroendocrinology 24, 823–32. 10.1016/S0306-4530(99)00039-6 [DOI] [PubMed] [Google Scholar]
  25. Everard A., Cani P. D. (2014). Gut microbiota and GLP-1. Rev. Endocr. Metab. Disord. 15, 189–196. 10.1007/s11154-014-9288-6 [DOI] [PubMed] [Google Scholar]
  26. Fteita D., Könönen E., Gürsoy M., Söderling E., Gursoy U. K. (2015). Does estradiol have an impact on the dipeptidyl peptidase IV enzyme activity of the Prevotella intermedia group bacteria? Anaerobe 36, 14–18. 10.1016/j.anaerobe.2015.09.002 [DOI] [PubMed] [Google Scholar]
  27. Fteita D., Musrati A. A., Kononen E., Ma X., Gursoy M., Peurla M., et al. (2017). Dipeptidyl peptidase IV and quorum sensing signaling in biofilm-related virulence of Prevotella aurantiaca. Anaerobe 48, 152–159. 10.1016/j.anaerobe.2017.08.009 [DOI] [PubMed] [Google Scholar]
  28. Gatti M., De Dea Lindner J., Gardini F., Mucchetti G., Bevacqua D., Fornasari M. E., et al. (2008). A model to assess lactic acid bacteria aminopeptidase activities in Parmigiano Reggiano cheese during ripening. J. Dairy Sci. 91, 4129–4137. 10.3168/jds.2008-1069 [DOI] [PubMed] [Google Scholar]
  29. Geier M. S., Tenikoff D., Yazbeck R., McCaughan G. W., Abbott C. A., Howarth G. S. (2005). Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J. Cell. Physiol. 204, 687–692. 10.1002/jcp.20333 [DOI] [PubMed] [Google Scholar]
  30. Glaser P., Rusniok C., Buchrieser C., Chevalier F., Frangeul L., Msadek T., et al. (2002). Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol. Microbiol. 45, 1499–1513. 10.1046/j.1365-2958.2002.03126.x [DOI] [PubMed] [Google Scholar]
  31. Goldstein J. M., Banbula A., Kordula T., Mayo J. A., Travis J. (2001). Novel extracellular x-prolyl dipeptidyl-peptidase (DPP) from Streptococcus gordonii FSS2: an emerging subfamily of viridans Streptococcal x-prolyl DPPs. Infect. Immun. 69, 5494–5501. 10.1128/IAI.69.9.5494-5501.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Gorrell M. D., Gysbers V., McCaughan G. W. (2001). CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54, 249–264. 10.1046/j.1365-3083.2001.00984.x [DOI] [PubMed] [Google Scholar]
  33. Guieu R., Fenouillet E., Devaux C., Fajloun Z., Carrega L., Sabatier J. M., et al. (2006). CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav. Brain Res. 166, 230–235. 10.1016/j.bbr.2005.08.003 [DOI] [PubMed] [Google Scholar]
  34. Hassan A. M., Jain P., Mayerhofer R., Fröhlich E. E., Farzi A., Reichmann F., et al. (2017). Visceral hyperalgesia caused by peptide YY deletion and Y2 receptor antagonism. Sci. Rep. 7:40968. 10.1038/srep40968 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hellström P. M., Hein J., Bytzer P., Bjornsson E., Kristensen J., Schambye H. (2009). Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment. Pharmacol. Ther. 29, 198–206. 10.1111/j.1365-2036.2008.03870.x [DOI] [PubMed] [Google Scholar]
  36. Hildebrandt M., Rose M., Ruter J., Salama A., Monnikes H., Klapp B. F. (2001). Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 36, 1067–1072. 10.1080/003655201750422675 [DOI] [PubMed] [Google Scholar]
  37. Holzer P., Reichmann F., Farzi A. (2012). Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides.46, 261–274. 10.1016/j.npep.2012.08.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hopsu-Havu V. K., Glenner G. G. (1966). A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7, 197–201. 10.1007/BF00577838 [DOI] [PubMed] [Google Scholar]
  39. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., et al. (2011). The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650, 249–255. 10.1016/j.ejphar.2010.10.008 [DOI] [PubMed] [Google Scholar]
  40. Kamble M., Gupta R., Rehan H. S., Gupta L. K. (2016). Neurobehavioral effects of liraglutide and sitagliptin in experimental models. Eur. J. Pharmacol. 774, 64–70. 10.1016/j.ejphar.2016.02.003 [DOI] [PubMed] [Google Scholar]
  41. Karagiannis T., Paschos P., Paletas K., Matthews D. R., Tsapas A. (2012). Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 344:e1369. 10.1136/bmj.e1369 [DOI] [PubMed] [Google Scholar]
  42. Klemann C., Wagner L., Stephan M., von Hörsten S. (2016). Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin. Exp. Immunol. 185, 1–21. 10.1111/cei.12781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kozakova H., Kolinska J., Lojda Z., Rehakova Z., Sinkora J., Zakostelecka M., et al. (2006). Effect of bacterial monoassociation on brush-border enzyme activities in ex-germ-free piglets: comparison of commensal and pathogenic Escherichia coli strains. Microbes Infect. 8, 2629–2639. 10.1016/j.micinf.2006.07.008 [DOI] [PubMed] [Google Scholar]
  44. Kozáková H., Reháková Z., Kolínská J. (2001). Bifidobacterium bifidum monoassociation of gnotobiotic mice: effect on enterocyte brush-border enzymes. Folia Microbiol. 46, 573–576. 10.1007/BF02818005 [DOI] [PubMed] [Google Scholar]
  45. Kozáková H., Stepánková R., Reháková Z., Kolínská J. (1998). Differences in enterocyte brush border enzyme activities in ageing rats reared in germ-free and conventional conditions. Physiol. Res. 47, 253–258. [PubMed] [Google Scholar]
  46. Laparra J. M., Sanz Y. (2010). Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J. Cell. Biochem. 109, 801–807. 10.1002/jcb.22459 [DOI] [PubMed] [Google Scholar]
  47. Lin Y., Krogh-Andersen K., Pelletier J., Marcotte H., Östenson C. G., Hammarstrom L. (2016). Oral delivery of pentameric glucagon-like peptide-1 by recombinant Lactobacillus in diabetic rats. PLoS ONE. 11:e0162733. 10.1371/journal.pone.0162733 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ma M., Hasegawa Y., Koibuchi N., Toyama K., Uekawa K., Nakagawa T., et al. (2015). DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc. Diabetol. 14:54. 10.1186/s12933-015-0218-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Magdy Y. M., El-Kharashi O. A., Nabih E. S., Shaker S. M., Abd-Elaziz L. F., Aboul-Fotouh S. (2017). Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. Biomed. Pharmacother. 85, 225–238. 10.1016/j.biopha.2016.10.098 [DOI] [PubMed] [Google Scholar]
  50. Marguet D., Baggio L., Kobayashi T., Bernard A. M., Pierres M., Nielsen P. F., et al. (2000). Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 97, 6874–6879. 10.1073/pnas.120069197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Mascolo A., Rafaniello C., Sportiello L., Sessa M., Cimmaruta D., Rossi F., et al. (2016). Dipeptidyl peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: a review of clinical cases. Drug Saf. 39, 401–407. 10.1007/s40264-016-0399-8 [DOI] [PubMed] [Google Scholar]
  52. Matos J., Nardi M., Kumura H., Monnet V. (1998). Genetic characterization of pepP, which encodes an aminopeptidase P whose deficiency does not affect Lactococcus lactis growth in milk, unlike deficiency of the X-prolyl dipeptidyl aminopeptidase. Appl. Environ. Microbiol. 64, 4591–4595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Mimura S., Ando T., Ishiguro K., Maeda O., Watanabe O., Ujihara M., et al. (2013). Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 48, 1152–1159. 10.3109/00365521.2013.832366 [DOI] [PubMed] [Google Scholar]
  54. Moran G. W., O'Neill C., Padfield P., McLaughlin J. T. (2012). Dipeptidyl peptidase-4 expression is reduced in Crohn's disease. Regul. Pept. 177, 40–45. 10.1016/j.regpep.2012.04.006 [DOI] [PubMed] [Google Scholar]
  55. Moulton C. D., Pickup J. C., Amiel S. A., Winkley K., Ismail K. (2016). Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: findings from the South London Diabetes (SOUL-D) Study. Prim. Care Diabetes 10, 156–159. 10.1016/j.pcd.2015.06.003 [DOI] [PubMed] [Google Scholar]
  56. Mulvihill E. E., Varin E. M., Gladanac B., Campbell J. E., Ussher J. R., Baggio L. L., et al. (2017). Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metab. 25, 152–165. 10.1016/j.cmet.2016.10.007 [DOI] [PubMed] [Google Scholar]
  57. Naveilhan P., Hassani H., Lucas G., Blakeman K. H., Hao J. X., Xu X. J., et al. (2001). Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 409, 513–517. 10.1038/35054063 [DOI] [PubMed] [Google Scholar]
  58. Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T. (2018). Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats. J. Gastroenterol. Hepatol. 33, 232–239. 10.1111/jgh.13808 [DOI] [PubMed] [Google Scholar]
  59. Olivares M., Neyrinck A. M., Pötgens S. A., Beaumont M., Salazar N., Cani P. D., et al. (2018). The DPP-4 inhibitor vildagliptin impacts the gut microbiota prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia 61, 1838–1848. 10.1007/s00125-018-4647-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Pedersen H. K., Gudmundsdottir V., Nielsen H. B., Hyotylainen T., Nielsen T., Jensen B. A., et al. (2016). Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381. 10.1038/nature18646 [DOI] [PubMed] [Google Scholar]
  61. Rawlings N. D., Barrett A. J., Finn R. (2016). Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 44, D343–D350. 10.1093/nar/gkv1118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Redrobe J. P., Dumont Y., Fournier A., Quirion R. (2002). The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26, 615–624. 10.1016/S0893-133X(01)00403-1 [DOI] [PubMed] [Google Scholar]
  63. Rigolet P., Xi X. G., Rety S., Chich J. F. (2005). The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity. FEBS J. 272, 2050–2059. 10.1111/j.1742-4658.2005.04631.x [DOI] [PubMed] [Google Scholar]
  64. Rosmaninho-Salgado J., Marques A. P., Estrada M., Santana M., Cortez V., Grouzmann E., et al. (2012). Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides 37, 49–54. 10.1016/j.peptides.2012.06.014 [DOI] [PubMed] [Google Scholar]
  65. Salaga M., Mokrowiecka A., Zielinska M., Malecka-Panas E., Kordek R., Kamysz E., et al. (2017). New peptide inhibitor of dipeptidyl peptidase, I. V., EMDB-1 extends the half-life of GLP-2 and attenuates colitis in mice after topical administration. J. Pharmacol. Exp. Ther. 363, 92–103. 10.1124/jpet.117.242586 [DOI] [PubMed] [Google Scholar]
  66. Sanz Y., Toldra F. (2001). Purification and characterization of an X-prolyl-dipeptidyl peptidase from Lactobacillus sakei. Appl. Environ. Microbiol. 67, 1815–1820. 10.1128/AEM.67.4.1815-1820.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Seino Y., Fukushima M., Yabe D. (2010). GIP and GLP-1, the two incretin hormones: similarities and differences. J. Diabetes Investig. 1, 8–23. 10.1111/j.2040-1124.2010.00022.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Shan L., Qiao S. W., Arentz-Hansen H., Molberg Ø., Gray G. M., Sollid L. M., et al. (2005). Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J. Proteome Res. 4, 1732–1741. 10.1021/pr050173t [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Shannon R. P. (2013). DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes 62, 1029–1031. 10.2337/db12-1794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Shibata Y., Miwa Y., Hirai K., Fujimura S. (2003). Purification and partial characterization of a dipeptidyl peptidase from Prevotella intermedia. Oral Microbiol. Immunol. 18, 196–198. 10.1034/j.1399-302X.2003.00057.x [DOI] [PubMed] [Google Scholar]
  71. Sommer F., Bäckhed F. (2013). The gut microbiota–masters of host development and physiology. Nat. Rev. Microbiol. 11, 227–238. 10.1038/nrmicro2974 [DOI] [PubMed] [Google Scholar]
  72. Stengel A., Goebel-Stengel M., Teuffel P., Hofmann T., Buße P., Kobelt P., et al. (2014). Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 61, 75–82. 10.1016/j.peptides.2014.09.006 [DOI] [PubMed] [Google Scholar]
  73. Sterkel A. K., Lorenzini J. L., Fites J. S., Subramanian Vignesh K., Sullivan T. D., Wuthrich M., et al. (2016). Fungal mimicry of a mammalian aminopeptidase disables innate immunity and promotes pathogenicity. Cell Host Microbe 19, 361–374. 10.1016/j.chom.2016.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Stressler T., Eisele T., Schlayer M., Lutz-Wahl S., Fischer L. (2013). Characterization of the recombinant exopeptidases PepX and PepN from Lactobacillus helveticus ATCC 12046 important for food protein hydrolysis. PLoS ONE 8:e70055. 10.1371/journal.pone.0070055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Üstün-Aytekin Ö., Arisoy S., Aytekin A., Ö Yildiz, E. (2016). Statistical optimization of cell disruption techniques for releasing intracellular X-prolyl dipeptidyl aminopeptidase from Lactococcus lactis spp. lactis. Ultrason Sonochem 29, 163–71. 10.1016/j.ultsonch.2015.09.010 [DOI] [PubMed] [Google Scholar]
  76. Varmanen P., Savijoki K., Avall S., Palva A., Tynkkynen S. (2000). X-prolyl dipeptidyl aminopeptidase gene (pepX) is part of the glnRA operon in Lactobacillus rhamnosus. J. Bacteriol. 182, 146–154. 10.1128/JB.182.1.146-154.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Walker N. D., McEwan N. R., Wallace R. J. (2003). Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384(T). Microbiology 149(Pt 8), 2227–2234. 10.1099/mic.0.26119-0 [DOI] [PubMed] [Google Scholar]
  78. Wallace R. J., McKain N., Broderick G. A., Rode L. M., Walker N. D., Newbold C. J., et al. (1997). Peptidases of the rumen bacterium, Prevotella ruminicola. Anaerobe 3, 35–42. 10.1006/anae.1996.0065 [DOI] [PubMed] [Google Scholar]
  79. Wang Z., Zeng X., Mo Y., Smith K., Guo Y., Lin J. (2012). Identification and characterization of a bile salt hydrolase from Lactobacillus salivarius for development of novel alternatives to antibiotic growth promoters. Appl. Environ. Microbiol. 78, 8795–8802. 10.1128/AEM.02519-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Zhong J., Gong Q., Goud A., Srinivasamaharaj S., Rajagopalan S. (2015). Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J. Diabetes Res. 2015:606031 10.1155/2015/606031 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (19KB, docx)

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon justified request.

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES